This article was originally published in The Gray Sheet
Executive SummaryExclusive licensing agreement with Heska Corp. focuses on the development and commercialization of Immulogic's recombinant allergen technology for diagnosis, immunotherapy and gene therapy for animals and humans. The company will receive license fees, milestone payments and royalties from Heska both for human and veterinary applications. The pact includes worldwide rights except in Japan where Immulogic has a non-exclusive license with Sankyo
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.